Amrita Y. Krishnan, MD, FACP and Nina Shah, MD
In this segment, “Next Steps in Multiple Myeloma”, Amrita Y. Krishnan, MD and Nina Shah, MD consider unmet needs and emerging therapeutic strategies.
Despite significant progress, additional new drugs and combinations are needed to improve outcomes of patients with multiple myeloma (MM). Currently, many different types of novel agents are in clinical trials for MM, including a diversity of targeted therapies, bispecific T-cell engagers, and BCMA-targeted immunotherapy/CAR-T cell therapies. Current research is studying how, or if, various therapies should be sequenced and/or combined.